REGENXBIO (RGNX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

REGENXBIO Revenue Highlights

Latest Revenue (Y)

$90.24M

Latest Revenue (Q)

$24.20M

Main Segment (Y)

License and Service

REGENXBIO Revenue by Period

REGENXBIO Revenue by Year

Date	Revenue	Change
2023-12-31	$90.24M	-19.94%
2022-12-31	$112.72M	-76.03%
2021-12-31	$470.35M	204.30%
2020-12-31	$154.57M	338.70%
2019-12-31	$35.23M	-83.88%
2018-12-31	$218.50M	2002.42%
2017-12-31	$10.39M	126.48%
2016-12-31	$4.59M	-39.52%
2015-12-31	$7.59M	23.99%
2014-12-31	$6.12M	0.54%
2013-12-31	$6.09M	-

REGENXBIO generated $90.24M in revenue during NA 2023, up -19.94% compared to the previous quarter, and up 41.30% compared to the same period a year ago.

REGENXBIO Revenue by Quarter

Date	Revenue	Change
2024-09-30	$24.20M	8.53%
2024-06-30	$22.30M	42.72%
2024-03-31	$15.62M	-29.67%
2023-12-31	$22.21M	-23.18%
2023-09-30	$28.91M	44.74%
2023-06-30	$19.98M	4.38%
2023-03-31	$19.14M	-38.94%
2022-12-31	$31.34M	18.23%
2022-09-30	$26.51M	-18.80%
2022-06-30	$32.65M	46.95%
2022-03-31	$22.22M	-94.43%
2021-12-31	$398.65M	1195.47%
2021-09-30	$30.77M	39.66%
2021-06-30	$22.04M	16.69%
2021-03-31	$18.88M	-11.94%
2020-12-31	$21.45M	-78.32%
2020-09-30	$98.91M	497.08%
2020-06-30	$16.57M	-6.11%
2020-03-31	$17.64M	49.93%
2019-12-31	$11.77M	-19.95%
2019-09-30	$14.70M	86.52%
2019-06-30	$7.88M	791.52%
2019-03-31	$884.00K	-97.83%
2018-12-31	$40.78M	668.51%
2018-09-30	$5.31M	-86.75%
2018-06-30	$40.03M	-69.76%
2018-03-31	$132.39M	6389.75%
2017-12-31	$2.04M	52.69%
2017-09-30	$1.34M	-79.64%
2017-06-30	$6.56M	1342.20%
2017-03-31	$455.00K	-73.17%
2016-12-31	$1.70M	1256.80%
2016-09-30	$125.00K	-94.74%
2016-06-30	$2.38M	504.33%
2016-03-31	$393.00K	-91.16%
2015-12-31	$4.45M	290.18%
2015-09-30	$1.14M	-16.36%
2015-06-30	$1.36M	111.65%
2015-03-31	$644.00K	-43.90%
2014-12-31	$1.15M	137.68%
2014-09-30	$483.00K	-

REGENXBIO generated $24.20M in revenue during Q3 2024, up 8.53% compared to the previous quarter, and up 121.12% compared to the same period a year ago.

REGENXBIO Revenue Breakdown

REGENXBIO Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
License and Service	$90.24M	$112.72M	-	-	-
License And Service	-	-	$470.35M	$154.57M	-
License	-	-	-	-	$3.50M
Zolgensma Royalties	-	-	-	-	$20.83M

REGENXBIO's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
License and Service	$24.20M	$22.30M	$15.62M	$70.27M	$19.98M	$31.34M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License And Service	-	-	-	-	-	$19.14M	$26.51M	$32.65M	$22.22M	$398.65M	$30.77M	$22.04M	$18.88M	-	-	-	-	-	-	-
Zolgensma Royalties	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$20.91M	$18.80M	$11.95M	$9.98M	$10.72M	-
License	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.50M	$3.50M	-	-
Achievement Of Sales Based Milestone For Zolgensma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$80.00M	-	-	-	-

REGENXBIO's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License and Service (100.00%).

REGENXBIO Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
IMCR	Immunocore	$249.43M	$75.40M
MIRM	Mirum Pharmaceuticals	$186.37M	$77.88M
RGNX	REGENXBIO	$90.24M	$24.20M
PTGX	Protagonist Therapeutics	$60.00M	$4.67M
QURE	uniQure	$15.84M	$2.29M
RVMD	Revolution Medicines	$11.58M	-
RNA	Avidity Biosciences	$9.56M	$2.04M
STOK	Stoke Therapeutics	$8.78M	$4.89M
KZR	Kezar Life Sciences	$7.00M	-
CRNX	Crinetics Pharmaceuticals	$4.01M	-
PLRX	Pliant Therapeutics	$1.58M	-
ANTX	AN2 Therapeutics	-	-
DAWN	Day One Biopharmaceuticals	-	$20.07M
REPL	Replimune Group	-	-
RCKT	Rocket Pharmaceuticals	-	-
PASG	Passage Bio	-	-
GLUE	Monte Rosa Therapeutics	-	$4.70M
FDMT	4D Molecular Therapeutics	-	-

RGNX Revenue FAQ

What is REGENXBIO’s yearly revenue?

REGENXBIO's yearly revenue for 2023 was $90.24M, representing a decrease of -19.94% compared to 2022. The company's yearly revenue for 2022 was $112.72M, representing a decrease of -76.03% compared to 2021. RGNX's yearly revenue for 2021 was $470.35M, representing an increase of 204.30% compared to 2020.

What is REGENXBIO’s quarterly revenue?

REGENXBIO's quarterly revenue for Q3 2024 was $24.2M, a 8.53% increase from the previous quarter (Q2 2024), and a -16.31% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $22.3M, a 42.72% increase from the previous quarter (Q1 2024), and a 11.60% increase year-over-year (Q2 2023). RGNX's quarterly revenue for Q1 2024 was $15.62M, a -29.67% decrease from the previous quarter (Q4 2023), and a -18.37% decrease year-over-year (Q1 2023).

What is REGENXBIO’s revenue growth rate?

REGENXBIO's revenue growth rate for the last 3 years (2021-2023) was -80.81%, and for the last 5 years (2019-2023) was 156.13%.

What are REGENXBIO’s revenue streams?

REGENXBIO's revenue streams in c 23 are License and Service

What is REGENXBIO’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of REGENXBIO was License and Service. This segment made a revenue of $90.24M, representing 100.00% of the company's total revenue.